199327-54-3

Basic information

• Product Name: Quinazoline, 4-chloro-7-(2-methoxyethoxy)-
• Synonyms: 4-Chloro-7-(2-methoxy-ethoxy)-quinazoline
• CAS NO: 199327-54-3
• Molecular Formula: C11H11ClN2O2
• Molecular Weight: 238.674
• Mol File: 199327-54-3.mol
• Article Data: 4

Chemical Properties

• Melting Point: 174 - 176 °C
• Boiling Point: 376.9±32.0 °C(Predicted)
• Density: 1.287±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Quinazoline, 4-chloro-7-(2-methoxyethoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: Quinazoline, 4-chloro-7-(2-methoxyethoxy)-(199327-54-3)
• EPA Substance Registry System: Quinazoline, 4-chloro-7-(2-methoxyethoxy)-(199327-54-3)

Safety Data

• Hazardous Substances Data: 199327-54-3(Hazardous Substances Data)

Upstream product

• 196194-86-2 7-(2-methoxyethoxy)-3,4-dihydroquinazolin-4-one 
• 446-32-2 4-fluoroanthranilic acid 
• 16499-57-3 7-fluoro-3H-quinazolin-4-one 
• 117324-05-7 2-amino-4-fluoro-benzoic acid ethyl ester 
• 1139573-82-2 2-methoxyethyl 4-(2-methoxyethoxy)-2-nitrobenzoate 
• 151504-81-3 methyl 4-fluoro-2-nitrobenzoate 

Relevant articles and documents

Design, synthesis and biological evaluation of pyrazolylaminoquinazoline derivatives as highly potent pan-fibroblast growth factor receptor inhibitors

Fibroblast growth factor receptors (FGFRs) are important oncology targets due to the dysregulation of this signaling pathway in a wide variety of human cancers. We identified a series of pyrazolylaminoquinazoline derivatives as potent FGFR inhibitors with low nanomolar potency. The representative compound 29 strongly inhibited FGFR1-3 kinase activity and suppressed FGFR signaling transduction in FGFR-addicted cancer cells; FGFRs-driven cell proliferation was also strongly inhibited regardless of mechanistic complexity implicated in FGFR activation, which further confirmed that 29 was a potent pan-FGFR inhibitor. The flexibility of our structure offered the potential to preserve good affinity for mutant FGFR, which is important for developing TKIs with long-term efficacy.

Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family

We have previously found that the 4-[4-(N-substituted carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazolines can function as potent and selective inhibitors of platelet-derived growth factor receptor (PDGFR) phosphorylation. A series of highly potent, specific, orally active, small molecule kinase inhibitors directed against members of PDGFR receptor have been developed through modifications of the novel quinazoline template I. Systematic modifications in the A-bicyclic ring and D-rings of protype I were carried out to afford potent analogues, which display IC50 values of 50 values of 50-200 nM, whereas 15-20-fold less potent activity against CSF1R was observed. This analogue also inhibits autophosphorylation of Flt-3 ligand-stimulated wild-type Flt-3 and a constitutively activated Flt-3/internal tandem duplication (ITD) with IC50 values of 30-100 nM. Through this optimization process, 75 was found to be metabolically stable and has desirable pharmacokinetic properties in all animal species studied (F% > 50%, T1/2 > 8 h). Oral administration of 75 promotes mice survival and significantly delayed disease progression in a Flt-3/ITD-mediated leukemia mouse model and shows efficacy in a nude mouse model of chronic myelomonocytic leukemia.